Summary: In adults with chronic diabetic foot ulcers, weekly topical Wharton’s jelly mesenchymal stem cell exosomes added to standard care produced complete healing in 62% with a mean healing time of 6 weeks versus 20 weeks for standard care, with minimal adverse events.
PICO Summary
| Element | Detail |
|---|---|
| Population | 110 adults with chronic non-healing diabetic foot ulcers (three groups). |
| Intervention | Weekly topical Wharton’s jelly-derived MSC exosomes plus standard of care for 4 weeks. |
| Comparison | Standard of care alone, and standard of care plus carboxymethyl cellulose (vehicle) placebo. |
| Outcome | 53/110 (62%) fully healed, significantly more than controls; mean healing 6 weeks (range 4–8) versus 20 weeks (range 12–28). Minimal adverse events. |
WJ-MSC exosomes for diabetic foot ulcers
RCT · chronic diabetic foot ulcers · 4-week treatment
Topical WJ-MSC exosomes added to standard care cut mean healing time to 6 weeks versus 20 weeks for controls. The effect is dramatic but the product is investigational, the control healing is strikingly slow, and there is no recurrence or amputation data.
Expert Commentary
A cell-free exosome preparation that delivers the regenerative signals of stem cells without the risks of live-cell engraftment is a genuinely attractive concept for the refractory diabetic foot, and the magnitude reported here, healing in six weeks against twenty, is the kind of effect that makes me sit up. It also makes me cautious, because effects that large in wound care are uncommon and the comparison deserves scrutiny. A twenty-week mean healing time in the control arm is strikingly slow and hints at either a severe population or constrained standard care, which would inflate the apparent benefit. Add a four-week intervention with little follow-up, no data on recurrence or amputation, and an exosome product whose dose and characterisation are not detailed, and I am left impressed but unconvinced. Can I use this with my patients? No, this is investigational and not standardised or approved, so it changes nothing in my practice today. Optimised standard care, debridement, offloading, vascular assessment, infection control, remains the foundation. I would want independent replication with hard endpoints and a clearly characterised product before believing an effect this dramatic.
References
Kishta MS, Hafez AM, Hydara T, et al. The transforming role of Wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial. Stem Cell Res Ther. 2025;16(1):559. doi:10.1186/s13287-025-04690-y